Neo-adjuvant Chemo and Immunotherapy in The Pre-operAtive Treatment of Locally Advanced cholangIOcarciNoma

Cholangiocarcinoma Clinical Trial

Official title:

Neo-adjuvant Chemo and Immunotherapy With Durvalumab (MEDI4736) and Tremelimumab (MEDI1123) In The Pre-operAtive Treatment of Locally Advanced cholangIOcarciNoma: an Exploratory and Translational Study.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06341764
• Other study ID #: CITATION
• Secondary ID: 7/23
• Status: Recruiting
• Phase: Phase 2
• Start date: September 1, 2023
• Est. completion date: September 2025

Study information

• Verified date: October 2023
• Source: National Cancer Institute, Naples
• Contact: Alessandro Ottaiano
• Phone: 08117770344
• Email: a.ottaiano[@]istitutotumori.na.it
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Neoadjuvant chemo- and immunotherapy ameliorate the recurrence rate of cholangiocarcinoma (CCA) at 12 months after surgery.

Description:

Multicenter, single arm, phase II study

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 38
• Est. completion date: September 2025
• Est. primary completion date: September 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Written informed consent and any locally required authorization (e.g., Health Insurance Portability and Accountability Act in the US, European Union [EU] Data Privacy Directive in the EU) obtained from the patient/legal representative prior to performing any protocol-related procedures, including screening evaluations.
• Histologically or pathologically confirmed CCA
• Age >18 years at time of study entry.
• Eastern Cooperative Oncology Group (ECOG) 0 or 1.
• Locally advanced disease (as assessed in multidisciplinary sessions).
• Life expectancy of at least 16 weeks.
• Body weight >30 kg
• Adequate normal organ and marrow function as defined below: Haemoglobin =9.0 g/dL
• Absolute neutrophil count (ANC =1.5 × 109 /L)
• Platelet count =100 × 109/L
• Serum bilirubin =1.5 x institutional upper limit of normal (ULN). This will not apply to patients with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physician.
• AST (SGOT)/ALT (SGPT) =2.5 x institutional upper limit of normal unless liver metastases are present, in which case it must be =5x ULN
• Measured creatinine clearance (CL) >40 mL/min or Calculated creatinine clearance CL>40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance.
• At least 1 lesion that qualifies as a RECIST 1.1 target lesion (TL) at baseline. Tumor assessment by computed tomography (CT) scan or magnetic resonance imaging (MRI) must be performed within 28 days prior to randomization.
• No previous systemic or local treatments including radiation therapy, radiofrequency ablations, electro-chemotherapy.

Exclusion Criteria:

• Any previous participation in another clinical interventional study.
• Concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable.
• History of allogenic organ transplantation.
• Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, interstitial lung disease, etc.]). The following are

exceptions to this criterion:

1. Patients with vitiligo or alopecia

2. Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement

3. Any chronic skin condition that does not require systemic therapy

4. Patients without active disease in the last 5 years may be included but only after consultation with the study physician

5. Patients with celiac disease controlled by diet alone

• Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, history of myocardial infarction within 12 months, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent
• History of bowel obstruction, refractory ascites, or bowel perforation due to advanced disease within the past 3 months from start of study treatment.
• Significant bleeding diathesis or coagulopathy. Serious, nonhealing wound, ulcer, or current healing fracture.
• History of another primary malignancy except for

1. Malignancy treated with curative intent and with no known active disease =5 years before the first dose of IP and of low potential risk for recurrence

2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease

3. Adequately treated carcinoma in situ without evidence of disease

• History of leptomeningeal carcinomatosis
• Brain metastases or spinal cord compression. Patients with suspected brain metastases at screening should have an MRI (preferred) or CT each preferably with IV contrast of the brain prior to study entry.
• History of active primary immunodeficiency.
• Known active hepatitis infection, positive hepatitis C virus (HCV) antibody, hepatitis B virus (HBV) surface antigen (HBsAg) or HBV core antibody (anti-HBc), at screening. Participants with a past or resolved HBV infection (defined as the presence of anti HBc and absence of HBsAg) are eligible. Participants positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
• Known to have tested positive for human immunodeficiency virus (HIV) (positive HIV 1/2 antibodies) or active tuberculosis infection (clinical evaluation that may include clinical history, physical examination and radiographic findings, or tuberculosis testing in line with local practice).
• Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab or tremelimumab. The following are exceptions to this criterion: Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection
• Systemic corticosteroids at physiologic doses not to exceed <<10 mg/day>> of prednisone or its equivalent
• Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)
• Receipt of live attenuated vaccine within 30 days prior to the first dose of IP.
• Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy or180 days after the last dose of durvalumab and tremelimumab combination therapy.
• Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.

Related Conditions & MeSH terms

• Cholangiocarcinoma

Intervention

Drug:
• Durvalumab 1120 mg
Durvalumab 1120 mg day 1 i.v
• Durvalumab 1500 mg
Durvalumab i.v. at 1500 mg once every 4 weeks
• Tremelimumab i.v. at 300 mg
Single dose

Combination Product:
• Cisplatin (CDDP) 25 mg/mq i.v
Four cycles
• Gemcitabine (GEM) 1000 mg/mq i.v.
Days 1 and 8 every 21 days

Locations

Country	Name	City	State
Italy	Istituto Nazionale Tumori di Napoli - IRCCS - Fondazione G. Pascale	Napoli	Italia
Italy	Ospedale Cardarelli, Napoli	Napoli	Italia
Italy	Università di Napoli "Federico II", Napoli	Napoli	Italia
Italy	Ospedale san Camillo Forlanini/Spallanzani, Roma	Roma	Italia
Italy	Ospedale Mauriziano, Umberto I°	Torino	Italia
Italy	Università di Verona, Ospedale Borgoroma, Verona	Verona	Italia

Sponsors (1)

Lead Sponsor	Collaborator
National Cancer Institute, Naples

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Exploratory objectives	Characterization of tumor microenvironment of primary CCAs and eventually resected metastases treated with neoadjuvant sequential chemo-immuno-therapy	24 months
Other	Exploratory objectives	Depiction of mutational evolution of CCA through NGS (Next Generation Sequencing) gene analysis on primary tumor biopsies and matched metastases (FFPE tissues or liquid biopsies).	24 months
Primary	Recurrence rate of CCA	To determine whether neoadjuvant chemo- and immunotherapy decrease the recurrence rate of CCA at 12 months after surgery.	24 months
Secondary	Rate of R0 resections	Rate of R0 resections (number of resections with surgical margins free from cancer/total number of resections) as assessed by pathologic examination (R1: microscopic disease.	24 months
Secondary	Radiologic responses	Radiologic responses evaluated through the RECIST v1.1 criteria.	24 months
Secondary	Pathologic responses	Pathologic responses (number of surgically removed tumour specimens with absence of any residual viable neoplastic cells).	24 months
Secondary	Toxicity assessed	Toxicity assessed by the NCI CTCAE v5.0	24 months
Secondary	PFS	Progression free survival (PFS) measured from study enrolment to death	24 months
Secondary	OS	Overall survival (OS) measured from study enrolment to death	24 months